Substandard and counterfeit medicines: a systematic review of the literature
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Objective: To explore the evidence available of poor-quality (counterfeit and substandard) medicines in the literature. Design: Systematic review. Data sources: Databases used were EMBASE, MEDLINE, PubMed and the International Pharmaceutical Abstracts, including articles published till January 2013. Eligibility criteria: Prevalence studies containing original data. WHO definitions (1992) used for counterfeit and substandard medicines. Study appraisal and synthesis: Two reviewers independently scored study methodology against recommendations from the MEDQUARG Checklist. Studies were classified according to the World Bank classification of countries by income. Data extraction: Data extracted: place of study; type of drugs sampled; sample size; percentage of substandard/counterfeit medicines; formulations included; origin of the drugs; chemical analysis and stated issues of counterfeit/substandard medicines. Results: 44 prevalence studies were identified, 15 had good methodological quality. They were conducted in 25 different countries; the majority were in low-income countries (11) and/or lower middle-income countries (10). The median prevalence of substandard/counterfeit medicines was 28.5% (range 11–48%). Only two studies differentiated between substandard and counterfeit medicines. Prevalence data were limited to antimicrobial drugs (all 15 studies). 13 studies involved antimalarials, 6 antibiotics and 2 other medications. The majority of studies (93%) contained samples with inadequate amounts of active ingredients. The prevalence of substandard/counterfeit antimicrobials was significantly higher when purchased from unlicensed outlets (p<0.000; 95% CI 0.21 to 0.32). No individual data about the prevalence in upper middle-income countries and high-income countries were available. Limitations: Studies with strong methodology were few. The majority did not differentiate between substandard and counterfeit medicines. Most studies assessed only a single therapeutic class of antimicrobials. Conclusions: The prevalence of poor-quality antimicrobial medicines is widespread throughout Africa and Asia in lower income countries and lower middle-income countries . The main problem identified was inadequate amounts of the active ingredients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Substandard medicines in resource‐poor settings: a problem that can no longer be ignored
Caudron, J. ‐., Ford, N., Henkens, M., Macé, C., Kiddle‐Monroe, R., & Pinel, J. (2008) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2008.02106.x · Cited by 332
Impact of poor-quality medicines in the ‘developing’ world
Newton, P. N., Green, M. D., & Fernández, F. M. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.11.005 · Cited by 289
Dondorp, A. M., Newton, P. N., Mayxay, M., Van Damme, W., Smithuis, F. M., Yeung, S., Petit, A., Lynam, A. J., Johnson, A., Hien, T. T., et al. (2004) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2004.01342.x · Cited by 240
Assessment of the incidence of substandard drugs in developing countries
Shakoor, O., Taylor, R. B., & Behrens, R. H. (1997) · Tropical Medicine & International Health · doi:10.1046/j.1365-3156.1997.d01-403.x · Cited by 228
The global counterfeit drug trade: Patient safety and public health risks
Mackey, T. K., & Liang, B. A. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22679 · Cited by 222
Pharmacopoeial quality of drugs supplied by Nigerian pharmacies
Taylor, R., Shakoor, O., Behrens, R., Everard, M., Low, A., Wangboonskul, J., Reid, R., & Kolawole, J. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05065-0 · Cited by 221
Guidelines for Field Surveys of the Quality of Medicines: A Proposal
Newton, P. N., Lee, S. J., Goodman, C., Fernández, F. M., Yeung, S., Phanouvong, S., Kaur, H., Amin, A. A., Whitty, C. J. M., Kokwaro, G. O., et al. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000052 · Cited by 214
How to achieve international action on falsified and substandard medicines
Attaran, A., Barry, D., Basheer, S., Bate, R., Benton, D., Chauvin, J., Garrett, L., Kickbusch, I., Köhler, J. C., Midha, K. K., et al. (2012) · BMJ · doi:10.1136/bmj.e7381 · Cited by 191
Antimalarial dosing regimens and drug resistance
Barnes, K. I., Watkins, W. M., & White, N. J. (2008) · Trends in Parasitology · doi:10.1016/j.pt.2007.11.008 · Cited by 161
Molecular epidemiology of malaria in Cameroon
Tahar, R., & Basco, L. K. (2007) · Acta Tropica · doi:10.1016/j.actatropica.2007.04.008 · Cited by 159
Basco, L. K. (2004) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2004.70.245 · Cited by 129
Onwujekwe, O., Kaur, H., Dike, N., Shu, E., Uzochukwu, B., Hanson, K., Okoye, V., & Okonkwo, P. (2009) · Malaria Journal · doi:10.1186/1475-2875-8-22 · Cited by 119
The Primacy of Public Health Considerations in Defining Poor Quality Medicines
Newton, P. N., Amin, A. A., Bird, C., Passmore, P. R., Dukes, G., Tomson, G. B., Simons, B., Bate, R., Guerin, P. J., & White, N. J. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001139 · Cited by 115
Counterfeit and substandard antimalarial drugs in Cambodia
Lon, C., Tsuyuoka, R., Phanouvong, S., Nivanna, N., Socheat, D., Sokhan, C., Blum, N., Christophel, E. M., & Smine, A. (2006) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/j.trstmh.2006.01.003 · Cited by 114
A Nationwide Survey of the Quality of Antimalarials in Retail Outlets in Tanzania
Kaur, H., Goodman, C. A., Thompson, E., Thompson, K., Masanja, I. M., Kachur, S. P., & Abdulla, S. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003403 · Cited by 76
Hadi, U., van den Broek, P., Kolopaking, E. P., Zairina, N., Gardjito, W., Gyssens, I. C., & the Study Group 'Antimicrobial Resistance in Indonesia: Prevalence and Prevention' (AMRIN) (2010) · BMC Infectious Diseases · doi:10.1186/1471-2334-10-203 · Cited by 72
The quality of drugs in private pharmacies in Lao PDR: a repeat study in 1997 and 1999
Syhakhang, L., Lundborg, C. S., Lindgren, B., & Tomson, G. (2004) · Pharmacy World & Science · doi:10.1007/s11096-004-0558-3 · Cited by 59
Chloroquine in the Ugandan market fails quality test: a pharmacovigilance study.
Ogwal-Okeng, J. W., Owino, E., & Obua, C. (2003) · African Health Sciences · Cited by 18
Cited by
Global antibiotic consumption and usage in humans, 2000–18: a spatial modelling study
Browne, A. J., Chipeta, M. G., Haines-Woodhouse, G., Kumaran, E. P. A., Hamadani, B. H. K., Zaraa, S., Henry, N. J., Deshpande, A., Reiner, R. C., Day, N. P. J., et al. (2021) · The Lancet Planetary Health · doi:10.1016/s2542-5196(21)00280-1 · Cited by 865
Essential medicines for universal health coverage
Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31599-9 · Cited by 661
Antimicrobial Stewardship: Fighting Antimicrobial Resistance and Protecting Global Public Health
Majumder, M. A. A., Rahman, S., Cohall, D., Bharatha, A., Singh, K., Haque, M., & Gittens-St Hilaire, M. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s290835 · Cited by 633
Ozawa, S., Evans, D. R., Bessias, S., Haynie, D. G., Yemeke, T. T., Laing, S. K., & Herrington, J. E. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.1662 · Cited by 356
Agyepong, I. A., Sewankambo, N., Binagwaho, A., Coll-Seck, A. M., Corrah, T., Ezeh, A., Fekadu, A., Kilonzo, N., Lamptey, P., Masiye, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31509-x · Cited by 245
Metadata
- Authors
- Almuzaini, T., Choonara, I., & Sammons, H.
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2013-08
- Volume
- 3
- Issue
- 8
- Pages
- e002923
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W2164318124
- Cited by
- 286
- References
- 22
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.